Ras (KRAS or NRAS) Gene Mutation clinical trials at UCSF

1 research study open to eligible people

Mutations in KRAS and NRAS genes can result in uncontrolled cell growth, causing cancer. UCSF is conducting trials with a new oral drug called NST-628 for those with solid tumors. Researchers are studying the drug's safety and how it moves through the body.

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for Ras (KRAS or NRAS) Gene Mutation research studies include .

Last updated: